Sulpin

Sulpin may be available in the countries listed below.

Ingredient matches for Sulpin

Sulpiride

Sulpiride is reported as an ingredient of Sulpin in the following countries:

• Taiwan

International Drug Name Search

Tuberculosis, Resistant Medications

Drugs associated with Tuberculosis, Resistant

The following drugs and medications are in some way related to, or used in the treatment of Tuberculosis, Resistant. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Drug List:

Paser-Controlled-Release-Granules-Packet

Utefos

Utefos may be available in the countries listed below.

Ingredient matches for Utefos

Tegafur

Tegafur is reported as an ingredient of Utefos in the following countries:

• Spain

International Drug Name Search

Vina-H3

Vina-H3 may be available in the countries listed below.

Ingredient matches for Vina-H3

Procaine

Procaine hydrochloride (a derivative of Procaine) is reported as an ingredient of Vina-H3 in the following countries:

• Vietnam

International Drug Name Search

Normolose-H

Normolose-H may be available in the countries listed below.

Ingredient matches for Normolose-H

Captopril

Captopril is reported as an ingredient of Normolose-H in the following countries:

• Greece

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Normolose-H in the following countries:

• Greece

International Drug Name Search

Pamine

See also: Generic Pamine Forte

Pamine is a brand name of methscopolamine, approved by the FDA in the following formulation(s):

PAMINE (methscopolamine bromide - tablet; oral)

• 
  Manufacturer: FOUGERA PHARMS
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 2.5MG ^[RLD][AA]

Has a generic version of Pamine been approved?

Yes. The following products are equivalent to Pamine:

methscopolamine bromide tablet; oral

• 
  Manufacturer: BOCA PHARMA
  
  Approval date: December 28, 2006
  
  Strength(s): 2.5MG ^[AA]


• 
  Manufacturer: BRECKENRIDGE PHARM
  
  Approval date: December 6, 2011
  
  Strength(s): 2.5MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pamine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Pamine.

See also...

• Pamine Consumer Information (Wolters Kluwer)
• Pamine Consumer Information (Cerner Multum)
• Pamine AHFS DI Monographs (ASHP)
• Methscopolamine Consumer Information (Wolters Kluwer)
• Methscopolamine Consumer Information (Cerner Multum)
• Methscopolamine Bromide AHFS DI Monographs (ASHP)

Xopenex HFA

See also: Generic Xopenex

Xopenex HFA is a brand name of levalbuterol, approved by the FDA in the following formulation(s):

XOPENEX HFA (levalbuterol tartrate - aerosol, metered; inhalation)

• 
  Manufacturer: SUNOVION
  
  Approval date: March 11, 2005
  
  Strength(s): EQ 0.045MG BASE/INH ^[RLD]

Has a generic version of Xopenex HFA been approved?

No. There is currently no therapeutically equivalent version of Xopenex HFA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xopenex HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for treating asthma using optically pure (R)-albuterol
  Patent 5,362,755
  Issued: November 8, 1994
  Inventor(s): Barberich; Timothy J. & Young; James W.
  Assignee(s): Sepracor, Inc.
  The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with chronic administration of racemic albuterol.
  
  Patent expiration dates:
  
  
  • March 25, 2013
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
  
  



• 
  Method for treating asthma using optically pure R(-) albuterol
  Patent 5,547,994
  Issued: August 20, 1996
  Inventor(s): Barberich; Timothy J. & Young; James W.
  Assignee(s): Sepracor, Inc.
  The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
  
  Patent expiration dates:
  
  
  • August 20, 2013
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
  
  



• 
  Medicinal aerosol formulations
  Patent 5,605,674
  Issued: February 25, 1997
  Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
  Assignee(s): Riker Laboratories, Inc.
  A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
  
  Patent expiration dates:
  
  
  • February 25, 2014
    
    ✓ 
    Drug product
  
  



• 
  Seals for use in an aerosol delivery device
  Patent 5,836,299
  Issued: November 17, 1998
  Inventor(s): Kwon; Oh-Seung
  Assignee(s): Minnesota Mining & Manufacturing Co.
  A device for delivering an aerosol, comprising: a casing member, a valve stem, and a diaphragm. The diaphragm is made of an ethylene-propylene-diene rubber ("EPDM") and is stable to dimensional change when exposed to 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoroethane.
  
  Patent expiration dates:
  
  
  • November 17, 2015
    
    ✓ 
    Drug product
  
  



• 
  Levalbuterol salt
  Patent 7,256,310
  Issued: August 14, 2007
  Inventor(s): McGlynn; Paul & Bakale; Roger & Sturge; Craig
  Assignee(s): Sepracor Inc.
  Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
  
  Patent expiration dates:
  
  
  • October 8, 2024
    
    ✓ 
    Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Xopenex HFA Aerosol Consumer Information (Wolters Kluwer)
• Xopenex HFA Consumer Information (Cerner Multum)
• Xopenex HFA Advanced Consumer Information (Micromedex)
• Levalbuterol Aerosol Consumer Information (Wolters Kluwer)
• Levalbuterol Solution Consumer Information (Wolters Kluwer)
• Levalbuterol Consumer Information (Cerner Multum)
• Xopenex Pediatric Advanced Consumer Information (Micromedex)
• Levalbuterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
• Levalbuterol AHFS DI Monographs (ASHP)